A share price of Organon & Co [OGN] is currently trading at $6.71, up 5.17%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The OGN shares have gain 2.13% over the last week, with a monthly amount drifted -34.47%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Organon & Co [NYSE: OGN] stock has seen the most recent analyst activity on October 27, 2025, when Piper Sandler downgraded its rating to a Underweight but kept the price target unchanged to $5 for it. Previously, Evercore ISI downgraded its rating to In-line on May 02, 2025. On September 06, 2024, downgrade downgraded it’s rating to Underweight and revised its price target to $20 on the stock. Goldman downgraded its rating to a Neutral and decreased its price target to $16 on November 03, 2023. Barclays initiated its recommendation with a Overweight and recommended $28 as its price target on September 21, 2023. Raymond James started tracking with an Outperform rating for this stock on March 16, 2023, and assigned it a price target of $33. In a note dated October 14, 2022, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $27 to $25.
Organon & Co experienced fluctuations in its stock price throughout the past year between $6.18 and $17.23. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Organon & Co [NYSE: OGN] shares were valued at $6.71 at the most recent close of the market. An investor can expect a potential drop of -25.48% based on the average OGN price forecast.
Analyzing the OGN fundamentals
Trailing Twelve Months sales for Organon & Co [NYSE:OGN] were 6.28B which represents -0.81% decline. Gross Profit Margin for this corporation currently stands at 0.56% with Operating Profit Margin at 0.21%, Pretax Profit Margin comes in at 0.11%, and Net Profit Margin reading is 0.11%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 1.25 and Total Capital is 0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of12.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.44 points at the first support level, and at 6.16 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.88, and for the 2nd resistance point, it is at 7.04.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Organon & Co [NYSE:OGN] is 1.65. In addition, the Quick Ratio stands at 1.13 and the Cash Ratio stands at 0.21. Considering the valuation of this stock, the price to sales ratio is 0.28, the price to book ratio is 2.38 and price to earnings (TTM) ratio is 2.49.
Transactions by insiders
Recent insider trading involved COX CARRIE SMITH, Director, that happened on May 14 ’25 when 12469.0 shares were purchased. Chief Human Resources Officer, Falcione Aaron completed a deal on May 07 ’25 to buy 5500.0 shares. Meanwhile, Gen. Counsel & Corp. Secy. Weaver Kirke bought 8045.0 shares on May 06 ’25.
